

SHANKS & HERBERT

Intellectual Property Advocates

TransPotomac Plaza, 1033 N. Fairfax St., Suite 306, Alexandria, VA 22314
Telephone: 703-683-3600 Facsimile: 703-683-9875 Email: Joseph@mail.ipadvocates.com

January 3, 2002

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Re: U.S. Patent Application
Serial No.: 09/704,554
Filed: November 3, 2000
For: Methods of Treating Amyloid β Precursor Disorders
Inventor(s): Friedhoff et al
Attorney Docket No.: 0200-0004

Sir:


The following documents are forwarded herewith for appropriate action by the
U.S. Patent and Trademark Office:

1. Transmittal Letter to the USPTO;
2. Amendment;
3. 3-month Extension of time;
4. Copies of second Preliminary Amendment and postcard filed February 14, 2001;
5. Our check in the amount of \$920.00 to cover the 3-month extension of time;
6. 1 return postcard

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

Respectfully submitted,

SHANKS & HERBERT


Joseph G. Contrera
Reg. No. 44,628

JGC:km

West Coast Office

4350 La Jolla Village Drive, Suite 330, San Diego, Ca 92122
Telephone: (858) 597-6688 Facsimile: (858) 597-6682

16174
RECEIVED
JAN 09 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

7/amdt A
CS
1-18-02



In re application of: Friedhoff et al.

Atty. Docket No.: 0200-0004

Appl. No.: 09/704,554

Examiner: Jiang, S.

Filed: November 3, 2000

Group Art Unit: 1617

For: METHOD OF TREATING
AMYLOID β PRECURSOR
DISORDERS

AMENDMENT

Assistant Director for Patents and Trademarks
Washington D.C. 20231

Sir:

In response to the Office Action dated July 3, 2001, in the above-referenced application, please make the following amendments:

In The Claims

Applicants note that the second preliminary amendment to this application made on February 14, 2001 does not appear to have been entered by the Examiner. A copy of the amendment and postcard is attached. The amendment added claims 34 and 35 which recited the following:

34. (New) A method of treating, preventing or inhibiting the progression of Alzheimer's disease in a mammal comprising administering to the mammal a controlled release composition comprising a therapeutically effective amount of at least one HMG-CoA reductase inhibitor.